Iran - Number of Confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) Cases
Since 2014, Iran Number of Confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) Cases jumped by 1.6% year on year. In 2019, the country was ranked number 180 among other countries in Number of Confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) Cases with 52 Cases. Iran is overtaken by Botswana, which was ranked number 179 with 53 Cases and is followed by Poland with 51 Cases. India ranked the highest with 66,255 Cases in 2019, a growth of 13.6% versus 2018. India, Russia and Russia respectively ranked number 2, 3 and 4 in this ranking. Republic of the Congo recorded the best 5 years average growth at +171.1% per year, while Croatia recorded the worst performance at -100% per year.
Loading...
| Date | Units (Cases) |
|---|---|
| 2019 | 52.00 |
| 2018 | 52.00 |
| 2017 | 52.00 |
| 2016 | 53.00 |
| 2015 | 58.00 |
How does Iran rank in Number of Confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) Cases?
| # | 359 Countries | Units (Cases) | Last | YoY | 5‑years CAGR | ||
|---|---|---|---|---|---|---|---|
| 1 |
#1
India
|
66,255 | 2019 | +13.6 % | +20.8 % | View data | |
| 3 |
#3
Russia
|
29,181 | 2019 | +5.0 % | +13.4 % | View data | |
| 178 |
#178
United Kingdom
|
56 | 2019 | -1.8 % | -2.3 % | View data | |
| 180 |
#180
Iran
|
52 | 2019 | +0.0 % | +1.6 % | View data | |
| 181 |
#181
Laos
|
51 | 2019 | -1.9 % | +16.3 % | View data | |